Skip to main content

Advertisement

Table 3 Difference in parameters with PFS > 4 months versus PFS ≤ 4 months

From: 18F-FDG and 11C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study

Modality Parameters PFS ≤ 4 months PFS > 4 months p value
CT Sum of uni-dimensional measurements of target lesions (cm) 74.6 ± 42.8 69.2 ± 23.2 0.87
FDG Highest SUVmax 12.8 ± 5.6 11.7 ± 4.4 0.95
Sum of SUVmax 38.8 ± 41.6 28.6 ± 21.4 0.90
MTV 138.0 ± 129.0 57.6 ± 43.5 0.19
TLG 707.9 ± 701.7 292.3 ± 240.7 0.21
SUL 10.0 ± 4.8 7.6 ± 3.3 0.28
%Δhighest SUVmax − 12.2 ± 37.8 − 12.0 ± 80.7 0.42
%Δsum of SUVmax − 19.2 ± 39.8 − 6.4 ± 85.1 0.79
%ΔMTV − 10.4 ± 59.4 − 29.1 ± 45.8 0.42
%ΔTLG − 10.9 ± 99.7 − 32.4 ± 79.0 0.33
%ΔSUL − 26.8 ± 47.5 − 34.4 ± 66.1 0.39
4DST Highest SUVmax 6.8 ± 2.4 5.7 ± 1.7 0.11
Sum of SUVmax 19.4 ± 17.8 22.8 ± 21.0 0.84
MTV 127.7 ± 127.8 50.3 ± 29.2 0.06
TLP 384.4 ± 371.0 158.4 ± 116.0 0.09
%Δhighest SUVmax 11.9 ± 37.3 − 5.6 ± 47.9 0.33
%Δsum of SUVmax 9.1 ± 49.5 − 18.6 ± 56.9 0.19
%ΔMTV − 18.9 ± 45.7 − 36.9 ± 52.4 0.33
%ΔTLP − 5.2 ± 77.9 − 32.9 ± 60.3 0.37
  1. MTV metabolic tumor volume, TLG total lesion glycolysis, SUL standardized uptake value normalized by lean body mass, TLP total lesion proliferation